Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 19/20 | 1.00 |
| ▸ | CTSL | P07711 | 16/20 | 1.00 |
| ▸ | CTSS | P25774 | 12/20 | 1.00 |
| ▸ | CTSB | P07858 | 6/20 | 1.00 |
| ▸ | CTSV | O60911 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4690508 | 0.86 | CTSK (0.74) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4765813 | 0.85 | CTSK (0.73) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4689513 | 0.81 | CTSK (0.67) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL14345772 | 0.79 | CTSK (0.64) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4764918 | 0.79 | CTSK (0.64) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL3046987 | 0.79 | CTSK (0.64) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL20915172 | 0.79 | CTSK (0.64) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5141688 | 0.78 | CTSK (0.75) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL7571991 | 0.76 | CTSK (0.64) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4861708 | 0.76 | CTSK (0.71) | CTSKCTSLCTSSCTSBCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9943522-B2 | Use of cathepsin K inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-04-17 | — | — | US | disclosed |
| US-20140155383-A1 | USE OF CATHEPSIN K INHIBITION FOR THE TREATMENT AND/OR PROPHYLAXIS OF PULMONARY HYPERTENSION AND/OR HEART FAILURE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155383-A1 | USE OF CATHEPSIN K INHIBITION FOR THE TREATMENT AND/OR PROPHYLAXIS OF PULMONARY HYPERTENSION AND/OR HEART FAILURE | CTSK, CTSF, CTSS | CTSK 1/4885CTSL 6/4885CTSS 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.